First Patient in the World Treated With Gene Therapy for Cockayne Syndrome
核心洞察
Riaan Singh Digeorge, age 6, became the first patient worldwide to receive an experimental AAV9 gene therapy (搜索) for Cockayne syndrome (搜索) on April 21, 2026, at NewYork-Presbyterian Komansky Children's Hospital.
The treatment was the culmination of a nearly five-year, parent-led effort by Riaan Research Initiative (搜索), which raised nearly $4 million and fully funded every step from preclinical studies to clinical administration.
Cockayne syndrome (搜索) is a severe DNA repair disorder with no FDA-approved treatments, causing brain atrophy, growth failure, and early death, with severely affected children having a life expectancy of 5 to 7 years.
Riaan Singh Digeorge, a 6-year-old boy from Queens, New York, has become the first patient in the world to receive an experimental gene therapy for Cockayne syndrome (搜索), a devastating and ultra-rare genetic disorder that causes premature aging and early death. The treatment was administered on April 21, 2026, at NewYork-Presbyterian Komansky Children's Hospital via a neurosurgical procedure performed by surgeon-in-chief Dr. Mark Souweidane. The milestone was announced on June 22, 2026, by Riaan Research Initiative (搜索) (RRI), the patient advocacy organization founded by Riaan's parents that spearheaded the entire drug development effort.
This achievement represents a landmark in parent-led rare disease drug development, demonstrating that families can drive therapeutic programs from concept to clinic when traditional pharmaceutical pathways fall short. Riaan's parents, Jo Kaur and Richard Digeorge, founded RRI in June 2021 shortly after their son's diagnosis and subsequently raised nearly $4 million to fund every stage of the program.
A Novel Gene Therapy Approach
The experimental therapy employs an adeno-associated viral vector serotype 9 (AAV9) to deliver a functional copy of the ERCC8/CSA (搜索) transgene directly to the brain. The approach targets the underlying genetic defect responsible for Cockayne syndrome (搜索), a severe DNA repair and transcription disorder for which no FDA-approved treatments currently exist.
The Investigational New Drug (IND) application was sponsored by UMass Chan Medical School, with Miguel Sena-Esteves, PhD, associate professor of neurology and genetic and cellular medicine and director of the Translational Institute for Molecular Therapeutics, serving as sponsor representative. The FDA cleared the IND application following promising preclinical results in mice, which demonstrated an 8.5-fold increase in lifespan among treated animals.
From Concept to Clinic: A Parent-Led Odyssey
The path to this first-in-human administration was forged through an intensive, nearly five-year effort that required RRI to build partnerships across the academic, manufacturing, and clinical ecosystem. The organization collaborated on and fully funded every step of the translational pipeline: preclinical studies at UMass Chan Medical School, toxicology studies at Charles River Laboratories, GMP manufacturing at Andelyn Biosciences (搜索), IND-enabling studies and regulatory submission, and finally the clinical administration at NewYork-Presbyterian in collaboration with Weill Cornell Medicine.
"Richie and I never imagined that our parenting journey would lead us to become drug developers, and we are grateful for the scientists and clinicians who helped us bring this treatment to our son," said Kaur. "It was not easy knowing he would be the first child in the world to receive the gene therapy. We were full of dueling emotions. But for hope, we took that leap. For love, we accepted the challenge."
Disease Burden and Unmet Need
Cockayne syndrome (搜索) is estimated to affect approximately 1 to 3 per one million people, placing it among the ultra-rare conditions where urgent patient needs often remain unmet under conventional drug development models. The disease is characterized by significant brain atrophy, growth failure, vision and hearing loss, developmental disabilities, and premature death. Children who are more severely impacted, like Riaan, have a life expectancy of just 5 to 7 years.
Early Post-Treatment Observations
In the two months since the procedure, Riaan has shown encouraging signs of resilience. "We are blown away by Riaan's superhuman resilience and good nature. He was laughing and playing balloon volleyball in PICU the day after neurosurgery," Kaur recounted. "It has been two months since treatment, and while it obviously hasn't been easy, Riaan's smile and zest for life carry us all forward. Each day brings excitement and possibility."
Looking Forward
RRI has expressed hope that this first-in-human experience will pave the way for broader access to the gene therapy for other children with Cockayne syndrome (搜索) who are awaiting treatment. The organization continues to advance both gene therapy and drug repurposing programs, underscoring the growing recognition that patient advocacy organizations can serve as powerful engines of translational research for ultra-rare diseases where commercial incentives remain limited.